Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Patients Following Ablation of Atrial Fibrillation by Park, Jeong-Hwan et al.
 
 
  185
ORIGINAL ARTICLE 
DOI 10.4070 / kcj.2009.39.5.185 
Print ISSN 1738-5520 / On-line ISSN 1738-5555
Copyright ⓒ 2009 The Korean Society of Cardiology
 
Effect of Angiotensin Converting Enzyme Inhibitors and 
Angiotensin Receptor Blockers on Patients Following Ablation 
of Atrial Fibrillation 
 
Jeong-Hwan Park, MD, Yong-Seog Oh, MD, Ji-Hoon Kim, MD, Woo-Baek Chung, MD, Su-Sung Oh, MD, 
Dong-Hyun Lee, MD, Yun-Seok Choi, MD, Woo-Seung Shin, MD, Chul-Soo Park, MD,   
Ho-Joong Youn, MD, Wook-Sung Chung, MD, Man-Young Lee, MD, Ki-Bae Seung, MD,   
Tae-Ho Rho, MD, Jae-Hyung Kim, MD and Soon-Jo Hong, MD 
Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea 
 
ABSTRACT 
Background and Objectives: It is known that angiotensin converting enzyme inhibitors and angiotensin II type 1 
receptor blockers (ACEIs and ARBs, respectively) are effective in preventing atrial fibrillation (AF) in high-risk 
patients. However, it is not known whether ACEIs and ARBs are effective in preventing the recurrence of AF after 
catheter ablation. Subjects and Methods: One hundred fifty-two patients (mean age, 57±10 years; M : F=94 : 58) 
who underwent catheter ablation due to drug-refractory paroxysmal (mean age, 57±10 years; M : F=58 : 43) or 
persistent AF (mean age, 56±10 years; M : F=36 : 15) were enrolled. We compared the recurrence rates between 
the groups with and without ACEIs or ARBs use in paroxysmal and persistent AF. The mean duration of follow-
up was 18±14 months. Results: The overall recurrence rate after ablation therapy was 26% (n=39). The recur-
rence rate was significantly decreased in the patients with persistent AF with the use of ACEIs or ARBs (12.1% vs. 
61.1%, p<0.01), but this difference was not observed in the patients with paroxysmal AF (24.2% vs. 22.9%, p= 
0.87). In patients with persistent AF with and without recurrence, the size of the left atrium (44.2±8.4 mm vs. 
44.3±5.8 mm, respectively, p=0.45) and the ejection fraction (62±6.5% vs. 61.5±6.2%, respectively, p=0.28) 
were not significantly different. In multivariate analysis, the use of ACEIs or ARBs was independently associated 
with recurrence after adjusting for the size of the left atrium and the ejection fraction {odds ratio (OR)=0.078, 95% 
confidence interval (CI)=0.02-0.35, p<0.01}. Conclusion: ACEIs and ARBs were shown to be effective in preventing 
AF recurrence after catheter ablation in patients with persistent AF. (Korean Circ J 2009;39:185-189) 
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Introduction 
 
Atrial fibrillation (AF) is the most common sustained 
cardiac arrhythmia and a major cause of substantial mor-
tality and morbidity from stroke, thromboembolism, and 
heart failure, leading to an impaired quality of life.
1-5) 
With the increase of elderly population in the developed 
world, the prevalence of AF is increasing, resulting in a 
major public health problem.
6) Maintenance of sinus rhy-
thm is the main therapeutic goal in patients with AF. 
Radiofrequency catheter ablation (RFCA) for AF has 
been proposed as an effective therapeutic option for AF 
that is resistant to pharmacologic rhythm or rate control, 
with successful long-term maintenance of sinus rhythm 
in the absence of treatment with anti-arrhythmic drugs 
reported in the majority of patients.
7) However, the re-
currence of AF after RFCA is not uncommon. The re-
currence rate of AF after RFCA has been reported to 
be between 30 and 40%, depending on the ablation 
strategy and the type of AF.
7-10) Some investigators have 
reported that the left atrial diameter/volume and hyper-
tension are predictors of AF recurrence after RFCA.
11)12) 
Recent research has focused increasingly on atrial st-
ructural remodeling and electrical dysfunction, which 
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underlie the development of AF in different pathologic 
conditions.
13-17) A particular interest has been generated 
in the role of renin-angiotensin system (RAS) blockade 
in reversing the electrical and structural remodeling of 
diseased atria.   
Angiotensin-converting enzyme inhibitors (ACEIs) 
are known to suppress structural and functional remo-
deling and prevent the induction and promotion of AF 
in chronic rapid atrial pacing dogs.
18) In several animal 
models, it has been suggested that angiotension II type 
1 receptor blockers (ARBs) might be useful for prevent-
ing AF recurrence after the termination of sustained AF 
by decreasing interstitial fibrosis.
19)20) However, there is 
still uncertainty about the role of ACEIs and ARBs for 
the reduction of AF recurrence after RFCA in clinical 
practice.  
This study was aimed to evaluate the effect of ACEIs 
and ARBs on the recurrence of AF after RFCA. 
  
Subjects and Methods  
 
We retrospectively evaluated 152 patients (mean age, 
57±10 years; M : F=94 : 58) who underwent AF abla-
tion due to drug-refractory paroxysmal (mean age, 57
±10 years; M : F=58 : 43) or persistent AF (mean age, 
56±10 years; M : F=36 : 15).  
Among the 152 patients, 101 had paroxysmal AF 
(PAF) and 51 had persistent AF (PeAF). PAF was de-
fined as the occurrence of two or more episodes of AF 
during the previous 12 months, typically lasting <7 days 
and terminating spontaneously. PeAF was defined as 
the occurrence of AF episodes lasting <7 days, and typi-
cally requiring cardioversion for restoration of normal 
sinus rhythm. The AF ablation strategy was 3D map-
ping (CARTO)-guided circumferential ablation, pulmon-
ary vein ostial ablation, and roof line, mitral valve isth-
mus, and right cavotricuspid isthmus block. AF ablation 
techniques were identical for all patients. 
After discharge, the patients were followed 1-2 weeks 
later, and then visited our hospital every 1-3 months 
during the first year after RFCA. Whenever the patients 
visited our clinic, a history was taken and a physical 
examination was performed. Additionally, a 12-lead ele-
ctrocardiography (ECG) and 24-hour ambulatory Hol-
ter ECG monitoring (24 hours Holter monitoring) were 
obtained. Thereafter, we immediately checked a 12-lead 
ECG and 24 hours Holter monitoring if the patients 
complained of symptoms, such as palpitations that sug-
gest AF. Twenty-four hours Holter monitoring was also 
performed on asymptomatic patients every 6 months. 
Recurrence was defined if the patients showed AF on 
a 12-lead ECG and/or on 24 hours Holter monitoring, 
or complained of typical episodes of palpitation sat the 
3-month follow-up visit after RFCA. 
We compared the recurrence rates between the PAF 
and PeAF groups that received ACEIs or ARBs. ACEIs 
or ARBs were prescribed at least 1 month prior to ab-
lation and for the duration of the follow-up. We used 
the standard doses that are generally recommended for 
ACEIs or ARBs. The mean follow-up duration was 18
±14 months. 
 
Statistical analysis 
The Statistical Package for Social Sciences (SPSS) for 
Windows, version 15.0 (Chicago, IL, USA) was used for 
all analyses. The continuous variables are presented as 
the mean values±standard deviations (SDs) and were 
compared using paired or unpaired Student’s t-tests. A 
p<0.05 was considered statistically significant.   
 
Results 
 
The PAF and PeAF groups, with or without ACEIs or 
ARBs, were similar with respect to important baseline 
clinical characteristics (Table 1 and 2). Furthermore, 
there was no difference in medications, including anti-
arrhythmic drugs other than ACEIs/ARBs for the PAF 
and PeAFFgroups (Table 3 and 4). 
The overall recurrence rate after ablation therapy was 
26% (n=39). In PAF patients, no significant differences 
existed in the recurrence rates between the group with 
ACEIs or ARBs and the group without ACEIs or 
ARBs (24.2% vs. 22.9%, p=0.87) (Fig. 1). However, in 
PeAF patients, compared with the group not using ACEIs 
or ARBs, the recurrence rate was significantly decre-
ased in the group using ACEIs or ARBs (12.1% vs. 
Table 1. Baseline clinical characteristics of the PAF patients
  PAF+A (n=66)  PAF-A (n=35)  p 
Age (years)  57.9±10 56.8±11 0.62 
Male, n (%)  39 (59.0)  19 (54.2)  0.36 
LA dimension (mm)  38.8±5 38.5±5 0.78 
LVEF (%)  63.1±7 62±7 0.44 
AF duration (months)  34±23 33±28 0.52 
Diabetes, n (%)  07 (10.6)  04 (11.4)  0.90 
Hypertension, n (%)  18 (27.2)  09 (25.7)  0.86 
COPD, n (%)  1 (1.5)  2 (5.7)  0.23 
CKD, n (%)  1 (1.5)  1 (2.8)  0.64 
CAD, n (%)  5 (7.5)  2 (5.7)  0.72 
LVH, n (%)  08 (12.1)  3 (8.5)  0.58 
Mitral stenosis, n (%)  3 (4.5)  2 (5.7)  0.79 
CRP (mg/L)  2.40±0.9 2.22±1.19 0.39 
Pro-BNP (pg/mL)  63±26 55±19 0.12 
Values are expressed as the means±SD. PAF+A: paroxysmal atrial
fibrillation with ACEIs or ARBs, PAF-A: paroxysmal atrial fibrilla-
tion wihout ACEIs or ARBs, LA: left atrium, LVEF: left ventricle 
ejection fraction, COPD: chronic obstructive pulmonary disease, 
CKD: chronic kidney disease, CAD: coronary artery disease, LVH:
left ventricle hypertrophy, CRP: C-reactive protein, Pro-BNP: Pro-
Brain natriuretic peptide, ACEIs: angiotensin converting enzyme 
inhibitors, ARBs: angiotensin II type 1 receptor blockers    
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61.1%, p<0.01) (Fig. 1).  
In PeAF patients with and without recurrence, the 
left atrium dimension (44.2±8.4 mm vs. 44.3±5.8 
mm, respectively, p=0.45) and the left ventricle ejection 
fraction (62±6.5% vs. 61.5±6.2%, respectively, p= 
0.28) were not significantly different. 
In multivariate analysis, the use of ACEIs or ARBs was 
independently associated with recurrence after adjust-
ing for the left atrium dimension and the left ventricle 
ejection fraction (OR=0.078, 95% CI=0.02-0.35, p< 
0.01). 
 
Discussion 
 
AF is a complex, multifactorial disease. The underly-
ing etiology is probably different in different patient 
subpopulations. The paroxysms of AF are consistently 
initiated by a spontaneous firing focus arising from se-
veral sites, including the pulmonary veins,
21-24) the vein 
of Marshall,
25) the coronary sinus,
23)26) the crista termi-
nalis,
23)26) the superior vena cava, and the inferior vena 
cava. The role of substrate is not as important as in PAF. 
However, electrophysiologic remodeling is commonly 
observed and is probably an important factor contri-
buting to the persistence of AF. In addition to eletro-
physiologic remodeling, structural remodeling, such as 
fibrosis (at both the subcellular and tissue levels) is also 
often present and contributes to the altered tissue sub-
strate that promotes AF maintenance.
27) 
Although there are many anti-arrhythmic drugs avail-
able to maintain sinus rhythm and reduce the ventricu-
lar rate, there is no drug which can control AF effectively. 
Because RFCA can effectively treat patients with drug-
refractory AF, RFCA has emerged as a major treatment 
option for AF. However, this procedure is limited by a 
significant rate of AF recurrence and the effect of RFCA 
on patients with PeAF is not as effective as on PAF. This 
phenomenon may be caused by structural and electrical 
remodeling of the atrium during the long period of AF. 
Several experimental studies have demonstrated that 
atrial cells express all components of RAS in a pig model 
of AF,
28) r emodeling of the  atriu m corr elated with  a 
high level of angiotensin in atrial tissue, and blockade 
of RAS through ACEIs or ARBs can reverse atrial re-
modeling.
13)18)29) Nakashima et al.
30) first demonstrated 
the role of ACEIs and ARBs in preventing atrial elec-
trical remodeling. They found that in dogs in which 
the atria were paced at 800 beats/min, candesartan and 
captopril prevented the atrial effective refractory period 
from shortening. 
In the current study, the overall recurrence rate after 
ablation therapy was 26% (n=39). The recurrence rate 
was significantly decreased in the PeAF group that used 
ACEIs or ARBs (12.1% vs. 61.1%, p<0.01). This result 
Table 4. Medications other than ACEIs or ARBs after catheter 
ablation for PeAF 
  PeAF+A 
(n=33) 
PeAF-A 
(n=18)  p 
Sotalol, n (%)  10 (30.3)  7 (38.8)  0.53 
Amiodarone, n (%)  05 (15.1)  4 (22.2)  0.52 
Flecainide, n (%)  15 (45.4)  6 (33.3)  0.40 
Propafenone, n (%)  3 (9.0)  1 (5.5)  0.65 
Beta-blcoker , n (%)  06 (18.1)  2 (11.1)  0.50 
Calcium channel blocker, n (%)  3 (9.0)  5 (27.7)  0.079 
Statin, n (%)  12 (36.3)  9 (50.0)  0.34 
Spironolactone, n (%)  2 (6.0)  1 (5.5)  0.94 
PeAF+A: persistent atrial fibrillation with ACEIs or ARBs, PeAF-A:
persistent atrial fibrillation wihout A CEIs or ARBs A CEIs: an-
giotensin converting enzyme inhibitors, ARBs: angiotensin II type 
1 receptor blockers 
 
Table 3. Medications other than ACEIs or ARBs after catheter
ablation for PAF 
  PAF+A 
(n=66) 
PAF-A 
(n=35)  p 
Sotalol, n (%)  40 (60.6)  20 (57.1)  0.73 
Amiodarone, n (%)  08 (12.1)  05 (14.2)  0.75 
Flecainide, n (%)  12 (18.1)  06 (17.1)  0.89 
Propafenone, n (%)  06 (9.0)  04 (11.4)  0.70 
Beta-blcoker, n (%)  12 (18.1)  08 (22.8)  0.37 
Calcium channel blocker, n (%)  05 (7.5)  06 (17.7)  0.14 
Statin, n (%)  35 (53.0)  21 (60.0)  0.32 
Spironolactone, n (%)  07 (10.6)  03 (8.5)  0.74 
PAF+A: paroxysmal atrial fibrillation with ACEIs or ARBs, PAF-
A: paroxysmal atrial fibrillation wihout ACEIs or ARBs, ACEIs:
angiotensin converting enzyme inhibitors, ARBs: angiotensin II
type 1 receptor blockers 
 
Table 2. Baseline clinical characteristics of the PeAF patients
  PeAF+A (n=33)  PeAF-A (n=18)  p 
Age (years)  54.1±10 58.0±9 0.21 
Male (%)  23 (69.6)  12 (66.6)  0.51 
LA dimension (mm)  43.8±6 44.7±7 0.65 
LVEF (%)  61.0±6 63.2±5 0.24 
AF duration (months)  21±10 24±11 0.38 
Diabetes, n (%)  10 (30.3)  04 (22.2)  0.53 
Hypertension, n (%)  13 (39.3)  06 (33.3)  0.66 
COPD, n (%)  2 (6.0)  01 (5.5)  0.94 
CKD, n (%)  1 (3.0)  01 (5.5)  0.65 
CAD, n (%)  3 (9.0)  01 (5.5)  0.60 
LVH, n (%)  04 (12.1)  02 (11.1)  0.91 
Mitral stenosis, n (%)  1 (3.0)  03 (16.6)  0.08 
CRP (mg/L)  2.63±1.47 2.76±1.25 0.75 
Pro-BNP (pg/mL)  98±43 88±25 0.37 
Values are expressed as the means±SD. PAF+A: paroxysmal atrial
fibrillation with ACEIs or ARBs, PAF-A: paroxysmal atrial fibrilla-
tion wihout ACEIs or ARBs, LA: left atrium, LVEF: left ventricle
ejection fraction, COPD: chronic obstructive pulmonary disease,
CKD: chronic kidney disease, CAD: coronary artery disease, LVH:
left ventricle hypertrophy, CRP: C-reactive protein, Pro-BNP: Pro-
brain natriuretic peptide, ACEIs: angiotensin converting enzyme 
inhibitors, ARBs: angiotensin II type 1 receptor blockers 
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might be caused by the effect of ACEIs or ARBs on al-
teration of left atrial remodeling and reduction of in-
terstitial fibrosis through RAS blockade. However, this 
difference in the recurrence rate was not observed in 
PAF patients (24.2% vs. 22.9%, p=0.87).  
We presume that the reason for this outcome might 
be caused by difference of pathophysiologic mechani-
sms between PAF and PeAF. That is to say, PAF is main-
ly triggered by electric foci, but electrophysiologic or 
structural remodeling underlie PeAF. Therefore, ACEIs 
or ARBs which can alter remodeling, played an im-
portant role in reducing the recurrence rate of PeAF, 
but not PAF.   
 
Conclusions 
ACEIs or ARBs might be effective in preventing AF 
recurrence after catheter ablation in PeAF patients.   
 
Limitations of the study 
This study had several limitations. First, this was a 
retrospective study. Second, this single-center study in-
cluded only a small number of patients. Therefore, fur-
ther prospective, randomized, large-scale studies are 
required.  
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Fig. 1. Comparison of recurrence rates between the persistent and paroxysmal atrial fibrillation groups with and without the use of ACEIs or 
ARBs. A: recurrence rate in persistent AF. B: recurrence rate in paroxysmal AF. ACEIs: angiotensin converting enzyme inhibitors, ARBs:
angiotensin II type 1 receptor blockers. 
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